- Home
- COE vs CMRX Comparison
COE vs CMRX Comparison
Compare COE & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- CMRX
- Stock Information
- Founded
- COE 2011
- CMRX 2000
- Country
- COE Singapore
- CMRX United States
- Employees
- COE N/A
- CMRX N/A
- Industry
- COE Other Consumer Services
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- CMRX Health Care
- Exchange
- COE Nasdaq
- CMRX Nasdaq
- Market Cap
- COE 76.7M
- CMRX 77.1M
- IPO Year
- COE 2016
- CMRX 2013
- Fundamental
- Price
- COE $15.45
- CMRX $2.89
- Analyst Decision
- COE
- CMRX Strong Buy
- Analyst Count
- COE 0
- CMRX 2
- Target Price
- COE N/A
- CMRX $8.50
- AVG Volume (30 Days)
- COE 10.3K
- CMRX 11.2M
- Earning Date
- COE 12-13-2024
- CMRX 11-07-2024
- Dividend Yield
- COE N/A
- CMRX N/A
- EPS Growth
- COE N/A
- CMRX N/A
- EPS
- COE N/A
- CMRX N/A
- Revenue
- COE $41,924,000.00
- CMRX $159,000.00
- Revenue This Year
- COE N/A
- CMRX N/A
- Revenue Next Year
- COE N/A
- CMRX $1,690.28
- P/E Ratio
- COE N/A
- CMRX N/A
- Revenue Growth
- COE 69.79
- CMRX N/A
- 52 Week Low
- COE $6.00
- CMRX $0.75
- 52 Week High
- COE $19.75
- CMRX $3.39
- Technical
- Relative Strength Index (RSI)
- COE 58.99
- CMRX 84.35
- Support Level
- COE $15.26
- CMRX $2.74
- Resistance Level
- COE $17.96
- CMRX $3.02
- Average True Range (ATR)
- COE 1.09
- CMRX 0.26
- MACD
- COE 0.33
- CMRX 0.18
- Stochastic Oscillator
- COE 68.88
- CMRX 77.13
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.